NMN/NR (Nicotinamide Mononucleotide/Riboside) Compassionate Use and Expanded Access

Understanding "Compassionate Use" for NMN and NR

True compassionate use, formally called Expanded Access under 21 CFR Part 312, applies to investigational drugs that have not yet received FDA marketing approval but are manufactured under an Investigational New Drug (IND) application. NMN and NR are currently sold in the United States as over-the-counter dietary supplements, not as INDs. That regulatory distinction matters enormously for anyone hoping to access these compounds through a formal expanded-access program.

Why Classic Expanded Access Does Not Apply

The FDA defines expanded access as a pathway for patients with serious or immediately life-threatening conditions to receive investigational drugs outside of a clinical trial when no comparable alternative exists. Because NMN and NR are available on the open market as supplements, neither the FDA nor any manufacturer can offer them under an Expanded Access IND in the traditional sense. A patient with a terminal mitochondrial disorder, for example, cannot petition the FDA for compassionate use of NMN the way a patient might petition for an unapproved oncology drug. The compound is simply not classified that way. FDA Expanded Access guidance explains the drug-classification prerequisite in plain language.

When IND Status Could Change This

At least one company, Metro International Biotech, filed with the FDA to reclassify NMN as an investigational new drug, arguing it was studied as a drug before being marketed as a supplement. If the FDA were to approve such a reclassification, formal compassionate use petitions would become possible. As of early 2026, that regulatory status remains unresolved. Researchers and clinicians tracking this should monitor the FDA's New Dietary Ingredient notification database and the Federal Register for updates. Pubmed coverage of the NMN regulatory debate provides useful context on the IND-exclusion provision.

What Clinical Evidence Exists to Support Access Requests?

Before requesting any form of subsidized or expanded access, a clinician needs to understand what the current evidence actually shows. Overstating the evidence base weakens any medical necessity argument.

Key Human Trials

The most-cited human trial is Yoshino et al. (2021), published in Science, which enrolled 25 postmenopausal women with prediabetes or obesity. Participants received NMN 250 mg/day for 10 weeks. NMN supplementation increased skeletal muscle insulin signaling and gene expression related to muscle remodeling compared with placebo, with blood NAD+ metabolites rising measurably. The effect size was modest but statistically significant at P<0.05 for several muscle-pathway endpoints. Yoshino et al. 2021 on PubMed.

Safety data from Liao et al. (2021, N=66) showed no serious adverse events at doses up to 1,250 mg NMN/day over four weeks. The most common complaints were mild gastrointestinal discomfort and flushing, similar to what has been reported with niacin at lower doses. Liao et al. 2021 safety trial.

For NR specifically, Elhassan et al. (2019, N=12) demonstrated that 1,000 mg NR/day for 21 days significantly increased whole-blood NAD+ in skeletal muscle of healthy, older men. No change in insulin sensitivity was detected at that timeframe. Elhassan et al. 2019.

What the Evidence Does Not Yet Show

No randomized controlled trial has demonstrated that NMN or NR reduces mortality, prevents a specific disease, or outperforms standard-of-care treatment for any FDA-recognized indication. The CALERIE-2 trial examined caloric restriction and aging biomarkers but did not test NAD+ precursors directly. Clinicians writing letters of medical necessity should confine their claims to what the evidence supports, specifically NAD+ metabolite elevation and preliminary metabolic signaling data, not longevity or disease reversal.

Clinical Trial Enrollment as a Cost-Free Access Pathway

Enrolling in an active clinical trial is the most medically legitimate way to receive NMN or NR at no cost while also contributing to the evidence base. ClinicalTrials.gov listed more than 40 active or recruiting trials involving NMN or NR as of early 2026.

Finding Relevant Trials

Search ClinicalTrials.gov using the terms "nicotinamide mononucleotide" or "nicotinamide riboside" filtered by "Recruiting" status. Trials are organized by condition. Conditions that have attracted the most NMN/NR trial activity include:

• Type 2 diabetes and prediabetes (metabolic endpoints)
• Age-associated muscle loss (sarcopenia)
• Cardiovascular aging biomarkers
• Fatty liver disease (NAFLD/MASLD)
• Long COVID fatigue and mitochondrial dysfunction

Eligibility criteria vary widely. Most trials exclude participants who are already supplementing with NAD+ precursors for at least four weeks before enrollment, so stopping supplementation early enough to qualify is a practical consideration.

What Participants Typically Receive

Most industry-sponsored trials provide the investigational compound at no charge, cover study-related lab work, and pay a modest visit stipend. Some academic trials cover only the compound. The trial protocol, available on ClinicalTrials.gov, specifies exactly what is and is not covered before consent. Participants should read Section 8 (Risk/Benefit) and the Compensation section of the informed consent form carefully.

Patient Assistance and Manufacturer Discount Programs

Because NMN and NR are supplements, not prescription drugs, they are not covered by traditional pharmaceutical patient assistance programs (PAPs) like those run by NeedyMeds or RxAssist. However, several manufacturers run their own cost-reduction programs.

Tiered Manufacturer Programs Available in 2026

The field of manufacturer programs changes frequently. The framework below describes the program types that existed across multiple NMN/NR brands as of early 2026. Verify current availability directly with each company.

Subscription discounts. Most major NMN/NR brands offer 10% to 20% savings when customers switch from single purchases to monthly auto-ship. Brands including Tru Niagen (NR, ChromaDex) and ProHealth NMN have offered this structure consistently.

Bulk purchasing tiers. Buying a 90-day or 180-day supply typically reduces per-unit cost by 15% to 30% compared to monthly single-unit orders. At standard doses (300 to 500 mg NMN daily), a 90-day supply from a reputable supplier ranges from $75 to $180.

Hardship programs. A small number of manufacturers offer income-based discount letters or codes for patients who can document financial hardship. These are not widely advertised. Contact the brand's customer service directly, provide your prescribing physician's contact information if asked, and request their "access assistance" or "hardship pricing" policy in writing.

Healthcare provider accounts. Some manufacturers offer accounts for licensed clinicians who order on behalf of patients. Discounts of 15% to 25% are common. Patients whose physicians use a telehealth-integrated supplement dispensary (such as Fullscript) may access wholesale pricing automatically.

HSA and FSA Eligibility for NMN and NR

This is one of the most frequently misunderstood areas. Over-the-counter supplements are generally not HSA/FSA eligible under IRS Publication 502 without additional documentation. The path to eligibility is specific.

The Letter of Medical Necessity Pathway

A Letter of Medical Necessity (LMN) written by a licensed physician or other qualified health professional can make an otherwise ineligible supplement reimbursable under an HSA or FSA. The IRS standard requires the expense to be primarily for the diagnosis, cure, mitigation, treatment, or prevention of disease, not for general health maintenance. IRS Publication 502 defines this threshold.

For NMN or NR to qualify, the physician's LMN should:

1. State the patient's specific diagnosis or confirmed risk condition (for example, type 2 diabetes, confirmed mitochondrial disorder, or prediabetes with documented insulin resistance).
2. Cite the specific compound, dose, and duration recommended.
3. Explain why this compound is medically appropriate for this patient's condition rather than for general wellness.
4. Be written on official letterhead, signed, and dated.

Without this document, HSA/FSA administrators will almost always reject NMN or NR reimbursement claims because the compounds are not on any approved-drug formulary.

Which Plans Accept the LMN

FSA and HSA plan administrators vary in their acceptance policies. Some third-party administrators (TPAs) require the LMN to be uploaded at the time of purchase. Others accept it retroactively during claim review. The patient should contact their TPA before purchasing to confirm the submission process. Purchases made through a dedicated HSA-eligible merchant (like the FSA Store or a pharmacy's HSA-eligible section) may auto-qualify or make the documentation process simpler.

Employees with a Limited-Purpose FSA (limited to dental and vision) cannot use this pathway for supplements regardless of the LMN.

Pricing Benchmarks and Cost Comparison by Dose

Understanding actual price ranges helps clinicians and patients assess whether cost-reduction strategies are working. The table below reflects publicly available retail pricing as of January 2026. Prices change; verify before purchase.

| Product | Dose per Day | Monthly Cost (Single Purchase) | Monthly Cost (Subscription) | |---|---|---|---| | Tru Niagen NR 300 mg | 300 mg NR | ~$40 | ~$32 | | Tru Niagen NR 600 mg | 600 mg NR | ~$65 | ~$52 | | ProHealth NMN 500 mg | 500 mg NMN | ~$55 | ~$44 | | Renue by Science NMN 500 mg (sublingual) | 500 mg NMN | ~$58 | ~$47 | | Alive by Science NMN 1,000 mg | 1,000 mg NMN | ~$90 | ~$72 |

Sublingual formulations are marketed as having higher bioavailability, though direct head-to-head bioavailability data in humans comparing sublingual NMN to oral NMN are limited. A 2023 crossover pharmacokinetic study (Yi et al., N=12) found that 500 mg sublingual NMN produced higher peak plasma NMN concentrations compared with the same oral dose, though total NAD+ elevation at 8 hours was not significantly different. Yi et al. 2023 PK study.

Compounding Pharmacies and Prescription NMN

A separate, less-discussed access route involves compounding pharmacies that prepare NMN as a prescription compound. This is distinct from buying a supplement.

How This Works

Some compounding pharmacies registered with the FDA under Section 503A of the Food, Drug, and Cosmetic Act prepare NMN powder in capsule form at physician-specified doses. The prescription pathway requires a licensed provider to write an order specifying dose, route, and indication. Because compounded preparations are not FDA-approved finished drugs, they are not covered by insurance, but they may be eligible for HSA/FSA reimbursement as prescription expenses without an additional LMN, since IRS rules treat compounded prescriptions as prescription drugs.

Compounded NMN pricing typically runs $60 to $130 per month depending on dose and pharmacy. The advantage is physician oversight and pharmacy-grade quality control. The disadvantage is that compounded preparations are not independently third-party tested the way some commercial supplements are (for example, NSF Certified for Sport or USP Verified supplements).

Physicians writing prescriptions for compounded NMN should be familiar with the 2023 FDA guidance on bulk drug substances used in compounding, which identifies compounds that may not be appropriate for 503A compounding. NMN is not on the current Category 1 (approved) or Category 2 (under review for removal) list as of January 2026, but this list is updated periodically. FDA 503A bulk drug substance list.

Evaluating Supplement Quality Before Purchase

Cost reduction strategies only make sense when paired with quality assurance. Several NMN and NR products on the market have failed independent purity testing.

Third-Party Certification Tiers

The most recognized independent certification programs for supplement quality are:

• NSF International (NSF Certified for Sport or NSF Contents Certified)
• USP Verification Program (USP Verified mark)
• Informed Sport / Informed Choice (relevant for athletes subject to doping controls)
• ConsumerLab.com (independent testing, subscription-based access to results)

A 2022 ConsumerLab analysis found that several NMN products contained significantly less NMN than labeled, with one product delivering only 57% of the stated dose. Patients comparing prices should account for actual dose delivered per dollar, not just labeled dose per dollar.

ChromaDex's NIAGEN (used in Tru Niagen) holds multiple patents on NR and has been the subject of published safety and efficacy studies, providing a stronger evidence anchor than generic NR products without such data. ChromaDex NR clinical data on PubMed.

What HealthRX Clinicians Consider Before Recommending NMN or NR

Not every patient is an appropriate candidate for NMN or NR supplementation, even with cost-reduction access in place. A thorough clinical assessment guides appropriate use.

Conditions Where Evidence Is Strongest

The best-supported clinical rationale for NMN or NR use, based on available RCT data, includes:

• Confirmed or borderline NAD+ deficiency states (rare metabolic conditions, confirmed via metabolomics panels)
• Type 2 diabetes or prediabetes with documented insulin resistance, where Yoshino et al. (2021) provides direct trial support
• Age-associated mitochondrial decline in patients over 60 with documented functional decline
• Post-chemotherapy fatigue in patients with documented mitochondrial toxicity from platinum-based or anthracycline regimens (mechanistic rationale; no large RCT yet)

Conditions Where Evidence Is Weak

General anti-aging use in otherwise healthy adults under 50 lacks RCT support. Longevity claims extrapolated from mouse studies (for example, Mills et al. 2016 in Cell Metabolism, which showed NMN reversed some aging phenotypes in mice) have not been reproduced in human RCTs at equivalent dose scaling. Mills et al. 2016.

How to Request an LMN Through HealthRX

HealthRX clinicians can issue a Letter of Medical Necessity for NMN or NR as part of a completed clinical consultation. The process requires:

1. A completed intake form including current diagnoses, recent labs (fasting glucose, HbA1c, lipid panel, and metabolic panel at minimum), and supplement history.
2. A synchronous or asynchronous consultation with a HealthRX provider who confirms a qualifying indication.
3. The LMN is issued digitally with the provider's NPI, state license number, and signature. It is valid for 12 months and can be reissued after an annual review.

Patients should download and retain the LMN before submitting any HSA/FSA claim. Keep a copy in your health records.

"The clearest path to coverage for NMN or NR is a well-documented clinical rationale tied to a specific, recognized metabolic or mitochondrial diagnosis. A letter that says 'for anti-aging' will not survive FSA audit." This reflects the standard position of the HealthRX medical team based on recurring FSA plan administrator feedback.